[
  {
    "ts": null,
    "headline": "Citi sees Gilead clinical holds as only ‘minor setback’",
    "summary": "Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated due to safety concerns, specifically decreases in CD4+ T-cell and absolute lymphocyte counts observed in a subset of participants receiving the combination therapy, the analyst tells investors in a research note. Citi says the se",
    "url": "https://finnhub.io/api/news?id=1ba49c6c0085df872da4e2c59f5c0d2319684ba82ba3c8f74e4aae32ccea1e59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749651619,
      "headline": "Citi sees Gilead clinical holds as only ‘minor setback’",
      "id": 135186783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated due to safety concerns, specifically decreases in CD4+ T-cell and absolute lymphocyte counts observed in a subset of participants receiving the combination therapy, the analyst tells investors in a research note. Citi says the se",
      "url": "https://finnhub.io/api/news?id=1ba49c6c0085df872da4e2c59f5c0d2319684ba82ba3c8f74e4aae32ccea1e59"
    }
  },
  {
    "ts": null,
    "headline": "Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital",
    "summary": "RBC Capital notes that Gilead (GILD) shared a statement that its weekly oral HIV treatment program 1720/4182 combo has been placed on a clinical hold following decreases in CD4 and lymphocyte counts observed in subset of patients. The firm’s view had been that ‘1720 had not been tested widely enough to de-risk on safety based on some lab findings in its earlier clinical studies and that there would be a high hurdle for market conversion once Biktarvy goes generic anyway even if this weekly oral",
    "url": "https://finnhub.io/api/news?id=e893248c5a91d5ed67ae5423ec9b19f1ecd8c0d2625c58af112b3594e7c3dc63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749651613,
      "headline": "Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital",
      "id": 135186785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "RBC Capital notes that Gilead (GILD) shared a statement that its weekly oral HIV treatment program 1720/4182 combo has been placed on a clinical hold following decreases in CD4 and lymphocyte counts observed in subset of patients. The firm’s view had been that ‘1720 had not been tested widely enough to de-risk on safety based on some lab findings in its earlier clinical studies and that there would be a high hurdle for market conversion once Biktarvy goes generic anyway even if this weekly oral",
      "url": "https://finnhub.io/api/news?id=e893248c5a91d5ed67ae5423ec9b19f1ecd8c0d2625c58af112b3594e7c3dc63"
    }
  },
  {
    "ts": null,
    "headline": "FDA placed clinical hold on Gilead HIV treatment trials of GS-1720",
    "summary": "The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182, the company said in a statement. The clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182, the company explained. It added, “Clinical trial investigators involved in the trials have been informed of these actions. GS-1720 and GS-",
    "url": "https://finnhub.io/api/news?id=d17d43316dd20a8b22c03b701890de2916c27011db7381e4bd2e686971d2ffab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749651320,
      "headline": "FDA placed clinical hold on Gilead HIV treatment trials of GS-1720",
      "id": 135186788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182, the company said in a statement. The clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182, the company explained. It added, “Clinical trial investigators involved in the trials have been informed of these actions. GS-1720 and GS-",
      "url": "https://finnhub.io/api/news?id=d17d43316dd20a8b22c03b701890de2916c27011db7381e4bd2e686971d2ffab"
    }
  },
  {
    "ts": null,
    "headline": "FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down",
    "summary": "GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.",
    "url": "https://finnhub.io/api/news?id=b03076d65c4432e3bb8d88b97bf4a1ca3d409d3c46915815c5429ae62e53a51a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749649620,
      "headline": "FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down",
      "id": 135186791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.",
      "url": "https://finnhub.io/api/news?id=b03076d65c4432e3bb8d88b97bf4a1ca3d409d3c46915815c5429ae62e53a51a"
    }
  },
  {
    "ts": null,
    "headline": "Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?",
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "url": "https://finnhub.io/api/news?id=3d5ee11e227c71adf53e0a8addc462e2017a2deaad4f1e4f5d943beb90512ec1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749648605,
      "headline": "Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?",
      "id": 135186794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
      "url": "https://finnhub.io/api/news?id=3d5ee11e227c71adf53e0a8addc462e2017a2deaad4f1e4f5d943beb90512ec1"
    }
  },
  {
    "ts": null,
    "headline": "1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finnhub.io/api/news?id=7b09b5f7ceab96b33e41faaaa19546a314090373e607914b10cdab01be03ed35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749616691,
      "headline": "1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar",
      "id": 135180171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
      "url": "https://finnhub.io/api/news?id=7b09b5f7ceab96b33e41faaaa19546a314090373e607914b10cdab01be03ed35"
    }
  },
  {
    "ts": null,
    "headline": "Tracking RenTech's 13F Portfolio - Q1 2025 Update",
    "summary": "RenTechâs Q1 2025 13F portfolio value decreased slightly to $66.07B. Check out the significant stake increases and major reductions in the portfolio.",
    "url": "https://finnhub.io/api/news?id=052b117f799eed2c573d9cf928e9f7d274bca070d09deafdfe5c1b0b7e7e4a08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749604283,
      "headline": "Tracking RenTech's 13F Portfolio - Q1 2025 Update",
      "id": 135173822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153363652/image_2153363652.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "RenTechâs Q1 2025 13F portfolio value decreased slightly to $66.07B. Check out the significant stake increases and major reductions in the portfolio.",
      "url": "https://finnhub.io/api/news?id=052b117f799eed2c573d9cf928e9f7d274bca070d09deafdfe5c1b0b7e7e4a08"
    }
  }
]